Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts

Cancer Biology and Therapy

Volumn 3, Issue 12, 2004, Pages 1217-1224

  Raut, Chandrajit P ^a   Nawrocki, Steffan ^a   Lashinger, Laura M ^a   Davis, Darren W ^a   Khanbolooki, Sanaz ^a   Xiong, Henry ^a   Ellis, Lee M ^a   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; bFGF; Celecoxib; COX 2; IL 8; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; INTERLEUKIN 8; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; VASCULOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; FIBROBLAST GROWTH FACTOR 2; MEMBRANE PROTEIN; PHOSPHOLIPASE A; PHOSPHOLIPASE A2 ALPHA; PHOSPHOLIPASE A2-ALPHA; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DENSITY; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; ENDOTHELIUM CELL; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INHIBITION KINETICS; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PARAMETER; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL CULTURE; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INDOMETHACIN; INTERLEUKIN-8; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PHOSPHOLIPASES A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22344443289     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.12.1221     Document Type: Article

References (29)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995; 76:1671-7.
3. Abbruzzese JL. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 2002; 29:2-8.
4. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871-5.
5. Holtzman MJ, Zhang V, Hussain H, Roswit W T, Wilson JD. Prostaglandin H synthase and lipoxygenase gene familles in the epithelial cell barrier. Ann NY Acad Sci 1994; 744:58-77.
6. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861-7.
7. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94:3336-40.
8. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13:1205-11.
9. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999; 26:69-76.
10. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59:4356-62.
11. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91:333-8.
12. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002; 118:194-201.
13. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990; 11:393-5.
14. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002; 94:1168-71.
15. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
16. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001; 1:291-9.
17. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 2001; 15:2742-4.
18. Eibl G, Reber HA, Wente MN, Hines OJ. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003; 26:33-41.
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-16.
20. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-11.
21. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31.
22. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418-23.
23. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential Involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003; 2:1-7.
24. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1:50-62.
25. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol 1997; 17:225-83.
26. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-8.
27. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300:754-61.
28. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-8, 1522 p following 1528.
29. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000; 284:1247-55.